Recently, the lab established macrophage-based adoptive transfer scenarios for congenital lung diseases and has pioneered cell and gene-therapy approaches for (myco)bacterial infections. Most recently, the lab was also able to establish scalable hematopoietic differentiation systems for human iPSC, which are able to continuously produce a multitude of hematopoietic cells. Thus, in close collaboration with the RG of Dr. Zweigerdt, we developed a unique technology of blood cell farming using industry compatible stirred tank bioreactors (the respetive IP and TecOffer can be downloaded in the "IP/Tec" section). This technology will now be further enhanced by technical advancements to generate a multitude of different hematopoietic cell types for future cell-therapy applications.